论文部分内容阅读
目的探讨门冬氨酸鸟氨酸(OA)联合促肝细胞生长素(HGF)治疗抗结核药物性肝炎的临床疗效。方法对2006年1月～2009年12月108例确诊为抗结核药物所致药物性肝炎住院患者按确诊先后顺序随机分为治疗组(54例)和对照组(54例),治疗组给予门冬氨酸鸟氨酸和促肝细胞生长素治疗;对照组应用常规护肝治疗。结果治疗组(54例)治愈34例,显效16例,有效4例,总有效率100%;对照组(54例)治愈21例,显效16例,有效4例,无效13例,总有效率75.9%。治疗4周,2组治疗效果有显著性差异(χ2=14.779,P<0.01)。治疗组疗效明显高于对照组,且无明显不良反应。结论门冬氨酸鸟氨酸联合促肝细胞生长素治疗抗结核药物所致药物性肝炎,能改善临床表现,有效恢复肝功能。
Objective To investigate the clinical efficacy of aspartate ornithine (OA) combined with hepatocyte growth-promoting factor (HGF) in the treatment of anti-TB drug-induced hepatitis. Methods From January 2006 to December 2009, 108 hospitalized patients with drug-induced hepatitis due to anti-TB drugs were randomly divided into treatment group (54 cases) and control group (54 cases) according to the order of diagnosis. The treatment group was given Aspartate ornithine and hepatocyte growth hormone treatment; the control group should be treated with conventional liver protection. Results In the treatment group (54 cases), 34 cases were cured, 16 cases were markedly effective, 4 cases were effective and the total effective rate was 100%. In the control group (54 cases), 21 cases were cured, 16 cases markedly effective, 4 effective and 13 ineffective. The total effective rate 75.9%. After 4 weeks of treatment, there was a significant difference between the two groups (χ2 = 14.779, P <0.01). The treatment group was significantly higher than the control group, and no significant adverse reactions. Conclusion Aspartate ornithine combined with hepatocyte growth-promoting drug treatment of drug-induced hepatitis caused by anti-TB drugs can improve clinical manifestations and effectively restore liver function.